我们如何预测患者的疾病进程以及他们是否会对特定治疗产生应答?
本文综述了炎症性肠病(IBD)中预测患者疾病进程及治疗应答或耐受性的研究进展。文章指出,随着治疗手段增多,治疗决策更加困难,而其他专科已开始利用疾病的分子异质性来提供答案。本文回顾了在预测IBD患者未来病程及对特定治疗应答或耐受方面所取得的进展。
要点
- IBD治疗决策困难,同一答案对不同患者可能效果迥异。
- 其他专科已开始利用分子异质性辅助临床决策。
- 本文综述了预测IBD病程及治疗应答或耐受性的研究进展。
核心结论
- 本文综述了预测IBD患者疾病进程及对特定治疗应答或耐受性的研究进展。
- 文章指出其他专科已开始利用疾病的分子异质性来提供答案。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 原文未报告具体研究数据或数值。
关键数值与推荐
- 原文未报告具体标准或数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gastroenterologists will be all too familiar with the difficult decisions that managing inflammatory bowel disease often presents. How aggressively should I treat this patient? Do I expect them to have a mild or aggressive form of disease? Do they need a biologic? If so, which one? And when should I start it? The reality is that the answers that would be right for one patient might be disastrous for another. The growing therapeutic armamentarium will only make these decisions more difficult, and yet, we have seen how other specialties have begun to use the molecular heterogeneity in their diseases to provide some answers. Here, we review the progress that has been made in predicting the future for any given patient with inflammatory bowel disease-whether that is the course of disease that they will experience or whether or not they will respond to, or indeed tolerate, a particular therapy.
引用
- Verstockt B, Parkes M, Lee JC, et al. How Do We Predict a Patient's Disease Course and Whether They Will Respond to Specific Treatments? Gastroenterology. 2022. PMID: 34995535. doi:10.1053/j.gastro.2021.12.245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。